Latest Updates

GBR 830 is the first antagonistic antibody targeting OX40 and is a potential Global First-in-class molecule

To invest Rs 80 crores in new project

Completes the tech transfer process for a new virally-transfected T-cell product

Experts from Argentina, Bangladesh, Brazil, China, Korea, Pakistan and the UK reflect growth of the MC

To address shortcomings of conventional high temperature polyimides currently available in the market

EBITDA margins grew by 67.6 per cent to Rs. 6,314 million

Has 22 years of experience as a public health consultant

Session to be held in Mumbai on February 15, 2013

EBITDA margin reported at 22.9 per cent

Over 20 countries set to participate at Bangalore INDIA BIO 2013 between February 4 and 6, 2013